Protective variant in PLCgamma2 mitigates Alzheimer's disease associated pathology via enhancing beneficial microglia functions
Mari Takalo,Heli Jeskanen,Taisia Rolova,Inka Kervinen,Marianna Hellen,Sami Heikkinen,Henna Koivisto,Kimmo Jokivarsi,Stephan A Muller,Esa-Mikko Koivumaki,Petra Makinen,SIni-Pauliina Juopperi,Roosa-Maria Willman,Rosa Sinisalo,Dorit Hoffman,Henna Jantti,Michael Peitz,Klaus Fliessbach,Teemu Kuulasmaa,Teemu Natunen,Susanna Kemppainen,Pekka Poutiainen,Ville Leinonen,Tarja Malm,Henna Martiskainen,Alfredo Ramirez,Annakaisa Haapasalo,Stefan F Lichtenthaler,Heikki Tanila,Christian Haass,Juha Rinne,Jari Koistinaho,Mikko Hiltunen
DOI: https://doi.org/10.1101/2024.09.12.612207
2024-09-14
Abstract:PLCgamma2-P522R (phospholipase C gamma 2, proline 522 to arginine) is a protective variant that reduces the risk for late onset Alzheimer's disease (LOAD). Recently, it was shown to decrease beta-amyloid pathology in 5XFAD mouse model of AD. In this study, our goal was to investigate the protective functions of PLCgamma2-P522R variant in less aggressive mouse model of AD as well as to assess underlying mechanisms at the molecular and cellular level using mouse and human microglia models.
The effects of the protective PLCgamma2-P522R variant on microglia activation, AD-related beta-amyloid and neuronal pathologies, as well as behavioral changes were investigated in PLCgamma2-P522R knock-in mice crossbred with an APP/PS1 mouse model of AD. Transcriptomic, proteomic, and functional studies were carried out in cultured and acutely isolated adult PLCgamma2-P522R mouse microglia to study molecular mechanisms. Finally, microglia-like cell models generated from blood and skin biopsy samples of the PLCgamma2-P522R variant carriers were employed to translate the key findings in human cells.
Our results demonstrate that the PLCgamma2-P522R variant reduces brain beta-amyloid plaque burden of APP/PS1 mice. Simultaneously, PLCgamma2-P522R variant increased non-proinflammatory microglia activation and microglia clustering around beta-amyloid plaques, leading to reduced beta-amyloid plaque-associated neuronal dystrophy. In cultured mouse primary microglia, PLCgamma2-P522R variant decreased accumulation of large lipid droplets, reduced cell stress, and increased acute response to strong inflammatory stimuli. Transcriptomic and proteomic analyses in acutely isolated adult mouse microglia as well as in human monocyte-derived microglial cells showed that PLCgamma2-P522R upregulates mitochondrial fatty acid oxidation and downregulates inflammatory/interferon signaling pathways. Accordingly, PLCgamma2-P522R increased mitochondrial respiration in iPSC -derived microglial cells.
Together, these findings suggest that PLCgamma2-P522R variant exerts protection against AD-associated beta-amyloid and neuronal pathologies via enhancing microglial barrier formation around beta-amyloid plaques, but suppressing pro-inflammatory activation. Observed changes in fatty acid metabolism and mitochondrial flexibility as well as the downregulation of genes involved in inflammatory signaling pathways suggest that these protective effects of the PLCgamma2-P522R variant are mediated through an anti-ageing mechanism.
Neuroscience